160
Participants
Start Date
September 1, 2020
Primary Completion Date
September 1, 2021
Study Completion Date
March 1, 2022
Evaluation of the degree of fibrosis and steatosis
The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.
Screening for the components of metabolic syndrome
"Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome."
Measurement of serum semaphorin concentrations
Semaphorin concentration will be measured in patient sera by ELISA.
Identification of semaphorin gene polymorphisms
Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.
University Hospital for Infectious Diseases Zagreb, Zagreb
Croatian Science Foundation
OTHER_GOV
University Hospital for Infectious Diseases, Croatia
OTHER